HC Wainwright & Co. reiterated coverage of Durect with a rating of Buy and set a new price target of $6.00
Chardan Capital reiterated coverage of Durect with a rating of Buy and set a new price target of $8.00 from $7.00 previously
4 - DURECT CORP (0001082038) (Issuer)
4 - DURECT CORP (0001082038) (Issuer)
4 - DURECT CORP (0001082038) (Issuer)
CUPERTINO, Calif., Sept. 4, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced management's participation in the H.C. Wainwright 26th Annual Global Investment Conference to take place September 9-11, 2024 in New York City. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious an
KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next
- FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis - Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Design - Seeking to Initiate Phase 3 Trial in 2024 with Topline Results Expected in 2H 2026 - Webcast of Earnings Call Today, August 13th at 4:30 p.m. ET CUPERTINO, Calif., Aug. 13, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the three months ended June 30, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigene
- FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis - Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Design - Seeking to Initiate Phase 3 Trial in 2024 with Topline Results Expected in 2H 2026 - Webcast of Earnings Call Today, August 13th at 4:30 p.m. ET CUPERTINO, Calif., Aug. 13, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the three months ended June 30, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigene
CUPERTINO, Calif., Aug. 7, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its second quarter financial results on Tuesday, August 13, 2024. Management will also host a conference call and webcast with investors to discuss financial results and provide a corporate update at 4:30 pm Eastern Time. Details for the call are as follows: www.durect.com) is a late-stage biopharmaceu
- FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Earnings Call Today, May 13th at 4:30 p.m. ET CUPERTINO, Calif., May 13, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the three months ended March 31, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer.
Submission status for DURECT CORP's drug POSIMIR (ORIG-1) with active ingredient BUPIVACAINE has changed to 'Approval' on 02/01/2021. Application Category: NDA, Application Number: 204803, Application Classification: Type 3 - New Dosage Form
SC 13G - DURECT CORP (0001082038) (Subject)
SC 13G - DURECT CORP (0001082038) (Subject)
SC 13G/A - DURECT CORP (0001082038) (Subject)
HC Wainwright & Co. analyst Ed Arce reiterates Durect (NASDAQ:DRRX) with a Neutral.
Gainers Rezolute (NASDAQ:RZLT) stock increased by 52.7% to $4.58 during Tuesday's after-market session. The company's market cap stands at $183.8 million. The company's, Q3 earnings came out 4 days ago. Mustang Bio (NASDAQ:MBIO) stock increased by 30.64% to $0.41. The company's market cap stands at $5.0 million. The company's, Q1 earnings came out 4 days ago. Qilian Intl Hldg Gr (NASDAQ:QLI) shares rose 14.77% to $0.87. The company's market cap stands at $31.1 million. MyMD Pharmaceuticals (NASDAQ:MYMD) shares increased by 12.68% to $2.31. The market value of their outstanding shares is at $4.9 million. The company's, Q4 earnings came out 4 days ago. Immunome (NASDAQ:IMNM) shares moved
KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next
CUPERTINO, Calif., March 21, 2023 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023. Ms. Maderis succeeds David Hoffmann as Chair of the Board. Mr. Hoffman has decided not to stand for re-election and will retire from the board on June 21, 2023 when his current term as a board member expires. "We thank Dave for his many years of service on the DURECT Board and wish him well," stated James E. Brown, D.V.M., President and CEO of DURECT. "Gail is a seasoned biopharmaceutical executive and we have benefitted from her innovative and strategic thinking as a board member since January
CUPERTINO, Calif., July 5, 2022 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a biopharmaceutical company focused on epigenetic regulation to develop treatments for acute organ injury and chronic liver diseases, today announced the appointment of Timothy M. Papp as its Chief Financial Officer. In this new role, Mr. Papp will direct and oversee all financial and capital markets activities including accounting, financial reporting, financial planning and analysis, financial strategy, and investor relations. "We are excited to welcome Tim to our executive leadership team, as he brings his deep understanding of corporate finance and corporate value drivers to DURECT," stated James E. Brown,
EFFECT - DURECT CORP (0001082038) (Filer)
S-3 - DURECT CORP (0001082038) (Filer)
10-Q - DURECT CORP (0001082038) (Filer)